Alterity to Detail MSA Trial Data, Phase 3 Plans in KOL Event
Event summary
- Alterity Therapeutics will host a virtual event on April 28-29, 2026, featuring Roy Freeman, Daniel Claassen, and CEO David Stamler.
- The event will focus on Multiple System Atrophy (MSA), a rare neurodegenerative disease with no approved treatments.
- Key topics include a review of Phase 2 trial data for Alterity’s lead candidate, ATH434, and an overview of planned Phase 3 program.
- Daniel Claassen serves as Chief Medical Advisor to Alterity Therapeutics, indicating a close strategic relationship.
The big picture
Alterity’s focus on MSA, a neglected rare disease, presents a high-risk, high-reward opportunity. The KOL event signals an attempt to bolster investor confidence and validate the Phase 2 data ahead of a pivotal Phase 3 trial. Success hinges on demonstrating a clear clinical benefit and navigating the complexities of a disease with limited understanding and no existing treatment options.
What we're watching
- Clinical Efficacy
- The detailed Phase 2 data presented will be critical in assessing ATH434’s true clinical benefit, as previous data has been mixed and the disease is difficult to measure.
- Phase 3 Design
- The specifics of the Phase 3 trial design will reveal Alterity’s strategy for demonstrating regulatory approval, particularly regarding endpoints and patient selection in a challenging disease.
- Advisor Alignment
- How Daniel Claassen’s role as CEO of Huntington’s Study Group and Chief Medical Advisor to Alterity influences the strategic direction and resource allocation for ATH434’s development warrants observation.
Related topics